Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergers

Eric Palmer Pfizer CEO Ian Read walked away from its $ 160 billion merger with Allergan this week after U.S. Treasury Department rule changes sucked the value out of its tax inversion ...

Vasopharm taps investors for €20M to fund PhIII trial of brain injury treatment

Nick Paul Taylor Vasopharm has emerged from talks with investors armed with €20 million ($ 22 million) to hustle its treatment for traumatic brain injury through Phase III. The ...

Investors look for Pfizer, Allergan, Mylan, Baxalta and others to address big questions at JP Morgan conference

Eric Palmer There are big questions facing some of pharma's key players this year, like whether the Pfizer and Allergan deal will get done and why Allergan thinks that is its best ...

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Carly Helfand Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers–including Evercore ISI analyst Umer Raffat, who ...

Virtual biotechs a hit with investors and, increasingly, buyers

Damian Garde Biotech venture capitalists have increasingly embraced the virtual model, seeding companies with promising assets, tiny staffs and a willingness to outsource. Now, as Reuters ...

GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

Carly Helfand GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty ...

Don’t get too excited, investors: GSK has no near-term plans for consumer health spinoff

Carly Helfand Let GlaxoSmithKline be clear: It's open to spinning off its consumer healthcare division at some nebulous point in the future. But it's not happening anytime soon. FiercePharma ...

Another Pfizer bid for AstraZeneca? Investors weigh in

Stacy Lawrence A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly ...

Biotech IPOs: Class of 2014 still rolling as investors line up to cash in

Damian Garde The most likely indicator of whether biotech's Wall Street hot streak can last is whether investors are getting good returns on all these drug developer IPOs. And so ...

Amarin is waiting till next year for an FDA decision on Vascepa, but investors are fine

Carly Helfand Amarin will have to wait until the new year to find out whether it's fish oil pill Vascepa will be approved for a wider indication. FiercePharma News

As FDA Decision Nears, Amarin CEO Retires And Investors Petition

esilverman Just days before the FDA is expected to decide whether to approve the controversial Vascepa fish oil pill that is sold by Amarin, the little drugmaker has announced ...

Biotech public records spur ‘arms race’ for investors

Damian Garde While pedestrian investors wait on press releases, conference calls and trial results before acting on biotech stocks, some of the world's largest hedge funds have ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS